COVID-19 pneumonia; predictors of severity and outcome in Erbil city hospitals
Keywords:Corona virus infection, Severity, Mortality, Dyspnea, Hypoxia
Background and objective: Corona infections disease nowadays is one of the major burden on national health institutes. The aim of the study is to identify the parameters that can predict the mortality in moderate to severely ill COVID-19 infected patients.
Methods: A prospective cross sectional study was carried out in Erbil Hospitals, Kurdistan region/Iraq from December 2020 to December 2021 on a sample of 100patients with positive real-time polymerase chain reaction. The data of enrolled patients were collected by direct interview with patients or with their relatives and filled in a prepared questionnaire. The patients were followed up from their admission to hospital until their discharge alive or dead.
Results: The mortality rate of hospitalized patients was 44% for 100 patients. Budesonide nebulizer were given to all of the patients. The mortality rate was significantly higher in old COVID-19 patients. The COVID-19 patients presented with dyspnea, hypertension and renal failure were significantly associated with higher mortality rates. High respiratory rate, low oxygen saturation and high C-reactive protein level were accompanied with higher mortality rates of COVID-19 patients.
Conclusion: The early predictors of mortality in patients with moderate to severe COVID-19 infection were elderly age, clinical presentation of dyspnea, clinical co-morbidity with hypertension and renal failure, high respiratory rate, low oxygen saturation and elevated levels of C-reactive protein.
Peeri NC, Shrestha N, Rahman MS, Zaki R, Tan Z, Bibi S, et al. The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: What lessons have we learned? Int J Epidemiol. 2020; 49(1):717–26. https://doi.org/10.5590/jcm11010328
World Health Organization. Coronavirus disease 20121 (COVID-19) weekly situation report (week 14). WHO Iraq. Available from: https://www.who.int/covid-19/information
Guan WJ, Ni ZY, Hu Y. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020; 382(18):1708–20. https://doi.org/10.1742/journal.pone.0298753
Wu, JT, Leung K, Bushman M, Kishore N, Niehus R, De Salazar PM, et al. Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China. Nat Med. 2020; 26(1): 506–10. https://doi.org/10.3567/jcm16789058
Ng O-T, Marimuthu K, Chia P-Y, Koh V, Chiew CJ, De Wang L, et al. SARS-CoV-2 Infection among Travelers Returning from Wuhan, China. N Engl J Med. 2020; 382(1): 1476–8. https://doi.org/10.7571/journal.pone.1056203
Bi Q, Wu Y, Mei S, Ye C, Zou X, Zhang Z, et al. Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: A retrospective cohort study. Lancet Infect Dis. 2020; 20(1):911–9. https://doi.org/15.3389/jcm1789065
Zhang J, Wang X, Jia X, Li J, Hu K, Chen G, et al. Risk factors for disease severity, unimprovement, and mortality in COVID-19 patients in Wuhan, China. Clin Microbiol Infect. 2020; 26(1):767–72. https://doi.org/7.3876/jcm876543
Kluge S, Nitschmann S, Scherer M. Inhaled budesonide in the treatment of COVID-19. Internist (Berl) 2021 ;62(8):887-9.doi: 10.1007/s00108-021-01071-4. Epub 2021 Jun 30.PMID: 34191054
Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, et al. Estimates of the severity of coronavirus disease 2019: A model-based analysis. Lancet Infect Dis. 2020; 20(1): 669–77. https://doi.org/10.3896/jcm9854328
Heinen N, Meister TL, Klöhn M, Steinmann E, Todt D, Pfaender S. Antiviral Effect of Budesonide against SARS-CoV-2. Viruses 2021; 13(7):1411. doi:10.3390/v13071411. PMID: 34372616
Bornstein SR, Rubino F, Khunti K. Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol. 2020; 8(6):546–50. doi:10.3550/v13071001. PMID: 12372616
Moe SS, Allan GM, Train A.Budesonide bests COVID-19. Can Fam Physician. 2022; 68(5):355–6. doi: 10.46747/cfp.6805355. PMID: 35552214
Louapre C, Collongues N, Stankoff B. Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis. JAMA Neurol. 2020; 77(9):1079–88. https://doi.org/8.3976/jcm119653210
Zhang X, Tan Y, Ling Y, Lu G, Liu F, Yi Z, et al. Viral and host factors related to the clinical outcome of COVID-19. Nat. Cell Biol. 2020; 583(1):437–40. https://doi.org/10.771/journal.pone.1117203
Fajnzylber J, Regan J, Coxen K, Corry H, Wong C, Rosenthal A, et al. SARS-CoV-2 viral load is associated with increased disease severity and mortality. Nat Commun. 2020; 11(1):1–9. doi:10.5789/ARM.a2021.1182. Epub 2021 Oct 20. PMID: 976438186
Li K, Wu J, Wu F, Guo D, Chen L, Fang Z, et al. The Clinical and Chest CT Features Associated with Severe and Critical COVID-19 Pneumonia. Investig Radiol. 2020; 55(1):327–31. doi: 10.5751/ARM.a2021.2182. Epub 2021 Oct 20.PMID: 34668056
Wu J, Li W, Shi X, Chen Z, Jiang B, Liu J, et al. Early antiviral treatment contributes to alleviate the severity and improve the prognosis of patients with novel coronavirus disease (COVID-19). J Intern Med. 2020; 288(1): 128–38. doi: 10.7790/v03071411. PMID: 04372616
Leung K, Wu JT, Liu D, Leung GM. First-wave COVID-19 transmissibility and severity in China outside Hubei after control measures, and second-wave scenario planning: A modelling impact assessment. Lancet. 2020; 395(1):1382–93. doi: 10.5664/ARM.a2021.0742. Epub 2021 Oct 20. PMID: 34790386
Rathi S, Ish P, Kalantri A, Kalantri S. Inhaled budesonide for mild COVID-19. Is there more to it than just airways? Adv Respir Med. 2021; 89(5):552–3. doi: 10.5603/ARM.a2021.0082. Epub 2021 Oct 20. PMID: 34668186
Omran D, Al Soda M, Bahbah E, Esmat G, Shousha H. Predictors of severity and development of critical illness of Egyptian COVID-19 patients: A multicenter study. PLOS ONE. 2021; 16(9):e0256203. Available from: https://doi.org/10.1371/journal.pone.0256203
Nguyen NT, Chinn J, De Ferrante M, Kirby KA, Hohmann SF, Amin A. Male gender is a predictor of higher mortality in hospitalized adults with COVID-19. PLoS One. 2021; 16(7):4066–7.
Mohammed IA, Ali AH, Al-Shenaty JA. Clinical course and disease outcomes in hospitalized patients with 2019 novel corona virus disease at Ibn- Al Khateeb Hospital in Baghdad, Iraq. J Fac Med Baghdad. 2020; 62(3):48–59. doi: 10.8603/ARM.a2021.5582. Epub 2021 Oct 20. PMID: 34668270
Perotte R, Sugalski G, Underwood JP, Ullo M. Characterizing COVID-19: A chief complaint based approach. Am J Emerg Med. 2021; 45(1):398–403.
Htun YM, Win TT, Aung A. Initial presenting symptoms, comorbidities and severity of COVID-19 patients during the second wave of epidemic in Myanmar. Trop Med Health. 2021; 49(1):62–3. doi: 10.8603/ARM.a2021.7782. Epub 2021 Oct 20. PMID: 34668344
Mammen JJ, Kumar S, Thomas L. Factors associated with mortality among moderate and severe patients with COVID-19 in India: a secondary analysis of a randomised controlled trial. BMJ Open. 2021; 11(1):571–2.
Aksel G, İslam MM, Algın A, Eroğlu SE, Yaşar GB, Ademoğlu E, et al. Early predictors of mortality for moderate to severely ill patients with Covid-19. Am J Emerg Med. 2021; 45(1):290–6. doi: 16.5673/ARM.a2021.0082. Epub 2021 Oct 20. PMID: 37648186
Chen J, Liu Y, Qin J. Hypertension as an independent risk factor for severity and mortality in patients with COVID-19: a retrospective study. Postgrad Med J. 2021; 1(1):674–5. doi: 10.1078/S2673-2600(21)08660-0. Epub 2021 Apr 9. PMID: 33844765
Pya Y, Bekbossynova M, Gaipov A, Lesbekov T, Kapyshev T, Kuanyshbek A, et al. Mortality predictors of hospitalized patients with COVID-19: Retrospective cohort study from Nur-Sultan, Kazakhstan. PLoS One. 2021; 16(12):272–3. Available from: https://doi.org/10.1371/journal. pone.0261272
Sepandi M, Taghdir M, Alimohamadi Y, Afrashteh S, Hosamirudsari H. Factors Associated with Mortality in COVID-19 Patients: A Systematic Review and Meta-Analysis. Iran J Public Health. 2020; 49(7):1211–21.
Nlandu Y, Mafuta D, Sakaji J. Predictors of mortality in COVID-19 patients at Kinshasa Medical Center and a survival analysis: a retrospective cohort study. BMC Infect Dis. 2021; 21(1): 1272–3. Available from: https://doi.org/10.1186/s12879-021-06984-x
Mukhtar A, Rady A, Hasanin A. Admission SpO2 and ROX index predict outcome in patients with COVID-19. Am J Emerg Med. 2021; 50(1):106–10.
Xie J, Covassin N, Fan Z. Association Between Hypoxemia and Mortality in Patients With COVID-19. Mayo Clin Proc. 2020; 95(6):1138–47. doi: 10.4590/v13071400. PMID: 34372336
Daval M, Corré A, Palpacuer C, Housset J, Poillon G, Verillaud B, et al Efficacy of local budesonide therapy in the management of persistent hyposmia in COVID-19 patients without signs of severity: A structured summary of a study protocol for a randomised controlled trial. 2020; 21(1):666–7. doi: 10.1186/s13063-020-04585-8. PMID: 32690074
Timpau AS, Miftode RS, Petris AO, Costache II, Miftode IL, Rosu FM, et al. Mortality Predictors in Severe COVID-19 Patients from an East European Tertiary Center: A Never-Ending Challenge for a No Happy Ending Pandemic. J Clin Med. 2022; 11(1):58–9. Available from: https://doi.org/10.3390/jcm11010058
Ramakrishnan S, Nicolau D, Langford B, Mahdi M, Jeffers H.Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomized controlled trial. Lancet Respir Med. 2021; 9(7):763–72. doi: 10.1016/S2213-2600(21)00160-0. Epub 2021 Apr 9. PMID: 33844996
How to Cite
Copyright (c) 2023 Halgurd Fathulla Ahmed, Zahir Hussein (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The copyright on any article published in Zanco J Med Sci is retained by the author(s) in agreement with the Creative Commons Attribution Non-Commercial ShareAlike License (CC BY-NC-SA 4.0).